Mazdutide
A GLP-1 and glucagon dual agonist developed with Innovent and Lilly, notable for obesity data and approval progress in China.
Also referenced as: IBI362, LY3305677
Also appears in: Hormone
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when Mazdutide crosses your target, drops, or sets a new tracked low—without daily noise.
This compound has a genuine development or study trail, but it is not an approved routine drug.
Primary research area: Metabolic. Also surfaces under Hormone for browsing and discovery.
IBI362, LY3305677
No FDA label signal · 44 trials · 51 PubMed results
Mazdutide has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.
Mazdutide has 37 name-matched clinical trials (highest phase: Phase 4) and 51 PubMed-indexed publications and is not FDA-approved. 1 trial has posted results.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What mazdutide is
Mazdutide is a GLP-1 / glucagon dual receptor agonist developed by Innovent and Lilly, best known right now for obesity and metabolic-disease development in China.
Why it matters
It belongs in the same broad family as other dual-agonist obesity drugs, but it matters on its own because it already has a meaningful clinical literature and has moved farther commercially in China than many pipeline names discussed in U.S.-centric peptide circles.
Regulatory context
Mazdutide is not FDA approved in the United States. It is best understood as an important international obesity-pipeline drug rather than an established U.S. therapy.
Practical reading note
Mazdutide is useful because it helps the library track not just what is popular in the U.S. market, but what is becoming important globally.